Differences in clinical characteristics and treatment outcomes of submacular hemorrhage caused by age-related macular degeneration and retinal macroaneurysms: A multicenter survey from the Japan Clinical Retina Study (J-CREST) group

• Published in: PloS one Vol. 17; no. 9; p. e0274508
• Main Authors: Kimura, Takeshi, Araki, Takashi, Yasukawa, Tsutomu, Kato, Aki, Kuwayama, Soichiro, Kinoshita, Takamasa, Okamoto, Fumiki, Murakami, Tomoya, Mitamura, Yoshinori, Sakamoto, Taiji, Terasaki, Hiroto, Kusuhara, Sentaro, Miki, Akiko, Takamura, Yoshihiro, Kondo, Mineo, Matsubara, Hisashi, Ueda, Tetsuo, Tsujinaka, Hiroki, Gomi, Fumi
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 29.09.2022; Public Library of Science (PLoS)
• Subjects: Acuity; Age; Age related diseases; Anticoagulants; Biology and Life Sciences; Care and treatment; Classification; Etiology; Eye diseases; Gas injection; Growth factors; Health aspects; Health services; Hemorrhage; Macular degeneration; Medical prognosis; Medical records; Medicine and Health Sciences; Multivariate analysis; Patient outcomes; Patients; Photodynamic therapy; Retina; Social Sciences; Statistical analysis; Thickness; Vascular diseases; Vascular endothelial growth factor; Visual acuity; Japan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0274508

Purpose To evaluate the clinical characteristics, treatment trends, and visual prognosis of submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD) and retinal arterial macroaneurysm (RAM). Methods This retrospective study enrolled 187 Japanese patients with SMH at 10 institutions from 2015 to 2018. Medical records including SMH etiology, best-corrected visual acuity (BCVA), fundus photographs, optical coherence tomography images, and selected treatments were analyzed. Results Major causes of SMH were typical nAMD (tnAMD) (18%), polypoidal choroidal vasculopathy (PCV) (50%) and RAM (29%). Age, male/female ratio, baseline BCVA, central retinal thickness, and involved retinal layers were significantly different between etiologies (all P<0.0001). Treatment with anti-vascular endothelial growth factor drugs with and without intravitreal gas injection was chosen for half of eyes in the tnAMD and PCV groups, whereas vitrectomy was performed in 83.7% of eyes with RAM. The final BCVA improved significantly from baseline in the PCV and RAM groups (P = 0.0009, P<0.0001) and final BCVA was significantly better in the PCV group at a level similar to the other groups (P = 0.0007, P = 0.0008). BCVA improvement from baseline was significantly greater in the RAM group compared with the tnAMD (P = 0.0152) and PCV (P = 0.017) groups. Multivariate analysis revealed better final BCVA was significantly associated with younger age (P = 0.0054), better baseline BCVA (P = 0.0021), RAM subtype (P = 0.0446), and no tnAMD (P = 0.001). Conclusions The characteristics of, and treatment strategy for, SMH were different between the underlying diseases. Anti-vascular endothelial growth factor treatment with or without expansile gas was mainly chosen for SMH in tnAMD and PCV, whereas vitrectomy with gas was the most common treatment for RAM, and the higher rate for vitrectomy might result in the greater BCVA improvement in the RAM group than in the other groups. Final BCVA was better in PCV, RAM, and tnAMD, in that order, because patients with PCV were younger and had better baseline BCVA.